(Q30954768)

27 June 2017

title

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival (English)

1 reference

27 June 2017

0 references

Harrow S

1

1 reference

27 June 2017

Papanastassiou V

2

1 reference

27 June 2017

Harland J

3

1 reference

27 June 2017

Mabbs R

4

1 reference

27 June 2017

Petty R

5

1 reference

27 June 2017

Fraser M

6

1 reference

27 June 2017

Hadley D

7

1 reference

27 June 2017

Patterson J

8

1 reference

27 June 2017

Brown SM

9

1 reference

27 June 2017

Rampling R

10

1 reference

27 June 2017

publication date

1 November 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

11

1 reference

27 June 2017

issue

22

1 reference

27 June 2017

page(s)

1648-1658

1 reference

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

HSV1716 persistence in primary human glioma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302289

21 January 2018

Identifiers

DOI

10.1038/SJ.GT.3302289

1 reference

27 June 2017

1 reference